Vol. 4, Issue 1, Part B (2024)

Post-translational modifications (PTMs) such as phosphorylation and acetylation are key regulatory mechanisms that govern a wide array of cellular processes, including transcription, DNA repair, chromatin remodelling, and protein stability. These dynamic and reversible modifications serve as molecular switches that influence protein interactions and signalling cascades. In the context of cancer biology, the dysregulation of PTMs is increasingly recognised as a major driver of tumour initiation, progression, metastasis, and resistance to therapy. Phosphorylation, primarily governed by kinases and phosphatases, is critical in activating pathways such as PI3K/AKT, MAPK, and Wnt/β-Catenin. Acetylation, catalysed by histone acetyltransferases (HATs) like Tip60, plays a significant role in gene expression regulation, particularly through chromatin modification and non-histone protein activity. This research provides a comprehensive, integrative analysis of phosphorylation and acetylation patterns in tumour progression, with a specific focus on their synergistic roles. Central to this analysis is the Tip60 β-Catenin KAI1 axis a mechanistic pathway involved in the transcriptional activation of metastasis suppressor genes. Tip60’s interaction with β-Catenin and its regulatory effect on KAI1 expression represents a compelling case of PTM crosstalk influencing metastatic behaviour. By combining recent experimental findings such as those in Tobias Kramer’s Tip60 β-Catenin dissertation) with proteomic database insights and network modelling (SEPTM and CCCN models), this study applies both molecular and systems biology perspectives. The analysis highlights how PTMs work in concert to modulate oncogenic processes, identifying critical regulatory nodes that serve as potential therapeutic targets. A data driven modelling approach is employed to visualise PTM hubs and their associated pathways across multiple tumour types, including prostate, lung, and colorectal cancers. The findings of this study propose that a dual-level understanding spanning detailed molecular mechanisms and global network interactions can unlock new avenues for biomarker discovery and targeted therapy development. Ultimately, this paper contributes to a growing body of research advocating the clinical relevance of PTM-based interventions in cancer treatment.